Proteotype Diagnostics is recruiting a Doctoral Candidate (DC14) as part of the HER-CARE Marie Skłodowska-Curie Doctoral Network, a European programme training the next generation of researchers in hereditary and early-stage breast cancer.
The project will focus on the development of circulating proteomic biomarkers for early breast cancer detection and prediction of treatment response, using Proteotype’s proprietary biomarker platform.
The doctoral candidate will:
Amsbio reports how researchers at the Graduate School of Medicine, Kyoto University (Japan) have cultured patient-derived colorectal cancer cells in 3D using their MatriMix 511 extracellular matrix (ECM).
In the race to bring new therapeutics to market, the biggest hurdles aren’t just scientific—they’re operational. Fragmented data and information fatigue can slow down even the most promising pipelines.
To help biotech leaders bridge these gaps, Digital Science has launched a comprehensive resource hub focused on Advancing R&D Excellence. This suite of resources provides the framework needed to make confident, evidence-based decisions at every stage of discovery.
The web is an amazing place where you can bank, shop, connect with people, be entertained, and so much more. Because the web is so integral to our daily and working lives you'd think everyone has equal access. But that's not always the case.
The team at Studio 24 are website accessibility experts and have built accessible websites for UK Parliament, HS2, RNIB and more. In this session you will learn:
Applications are invited for a Postdoctoral Research Scientist to join the Laboratory of Dr Sarah Guiziou, and more generally the engineering biology consortium of the Earlham Institute, based in Norwich, UK.
At Cancer Research UK, we exist to beat cancer.
To help us with our mission we have an exciting opportunity for an experienced Head of Biometrics and Medical Writing to join us and lead the Biometrics & Medical Writing functional group to effectively deliver CDD clinical trials to the appropriate regulatory and quality standards in the UK and EU.
About the team
Mestag Therapeutics is a clinical-stage biotechnology company pioneering the discovery and development of antibody therapeutics targeting cancer and inflammatory disease. Our science is rooted in fibroblast immunology, leveraging cutting-edge biological and translational insights to uncover novel pathways that drive immune modulation in disease.
Mestag is backed by committed leading global investors, has world-class founders and a highly experienced leadership team.
Domainex is a multi‑award‑winning integrated drug discovery CRO that has been setting the highest standards in small‑ and large‑molecule research since 2001. We partner with academic groups, biotechs, pharma companies and patient foundations worldwide to deliver high‑quality science that accelerates innovative therapies to patients.
Transforming Patient Care Through Innovation
Executive Summary